Have a feature idea you'd love to see implemented?
Let us know!
DARE Dare Bioscience Inc
Price (delayed)
$3.23
Market cap
$28.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.58
Enterprise value
$17.73M
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse
Highlights
DARE's net income has surged by 91% year-on-year and by 50% since the previous quarter
DARE's EPS has surged by 90% year-on-year and by 48% since the previous quarter
The equity has plunged by 156% from the previous quarter but it has grown by 35% YoY
The company's gross profit has surged by 92% YoY but it fell by 34% QoQ
Key stats
What are the main financial stats of DARE
Market
Valuations
Earnings
Shares outstanding
8.7M
Market cap
$28.1M
Enterprise value
$17.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
14.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.42
Revenue
$1.88M
EBIT
-$3.6M
EBITDA
-$3.49M
Free cash flow
-$8.63M
Per share
Balance sheet
Liquidity
EPS
-$0.58
Free cash flow per share
-$1.01
Book value per share
-$0.17
Revenue per share
$0.22
TBVPS
$2.12
Total assets
$18.06M
Total liabilities
$19.54M
Debt
$1.4M
Equity
-$1.48M
Working capital
$1.79M
Debt to equity
-0.95
Current ratio
1.14
Quick ratio
0.93
Net debt/EBITDA
2.98
Margins
Efficiency
Dividend
EBITDA margin
-185.3%
Gross margin
96.9%
Net margin
-191.6%
Operating margin
-1,235%
Return on assets
-19%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-73.5%
Return on sales
-191.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DARE stock price
How has the Dare Bioscience stock price performed over time
Intraday
1.57%
1 week
-9.4%
1 month
-11.14%
1 year
-20.64%
YTD
-12.94%
QTD
-0.31%
Financial performance
How have Dare Bioscience's revenue and profit performed over time
Revenue
$1.88M
Gross profit
$1.82M
Operating income
-$23.23M
Net income
-$3.6M
Gross margin
96.9%
Net margin
-191.6%
The net margin has soared by 95% year-on-year and by 24% since the previous quarter
The company's gross profit has surged by 92% YoY but it fell by 34% QoQ
DARE's net income has surged by 91% year-on-year and by 50% since the previous quarter
DARE's revenue has soared by 88% YoY but it is down by 34% QoQ
Growth
What is Dare Bioscience's growth rate over time
Valuation
What is Dare Bioscience stock price valuation
P/E
N/A
P/B
N/A
P/S
14.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.42
DARE's EPS has surged by 90% year-on-year and by 48% since the previous quarter
The equity has plunged by 156% from the previous quarter but it has grown by 35% YoY
DARE's revenue has soared by 88% YoY but it is down by 34% QoQ
The price to sales (P/S) is 9% higher than the last 4 quarters average of 13.4
Efficiency
How efficient is Dare Bioscience business performance
DARE's return on sales has surged by 95% year-on-year and by 24% since the previous quarter
The ROA has soared by 86% YoY and by 45% from the previous quarter
Dividends
What is DARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DARE.
Financial health
How did Dare Bioscience financials performed over time
The total assets is 8% less than the total liabilities
The company's quick ratio rose by 45% YoY but it fell by 24% QoQ
The current ratio has grown by 34% YoY but it has contracted by 20% from the previous quarter
The debt is 195% greater than the equity
The equity has plunged by 156% from the previous quarter but it has grown by 35% YoY
The debt has declined by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.